

VERTEX PHARMACEUTICALS INC.

ISIN: US92532F1003 WKN: 92532F100 Asset Class: Stock

Company



2024/04/19 22:00:00

Price
394.28
USD

Difference 0.20%(0.80)



Contact Details

VERTEX PHARMACEUTICALS
INC.

--

50 Northern Avenue

02210 Boston

Tel: +1-617-341-6100

Fax: +

Web: <http://www.vrtx.com>

E-mail:
mediainfo@vrtx.com

Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	14,144,200,000		13,234,800,000		9,560,600,000	
Common stock capital		2,600,000		2,600,000		2,500,000
Fixed assets	8,942,100,000		4,916,100,000		3,871,900,000	
Equity capital of a company		17,580,400,000		13,912,700,000		10,100,000,000
Cash and cash equivalents	10,372,300,000		10,512,000,000		6,800,100,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		3,547,400,000		2,742,100,000		2,142,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,958,500,000		1,496,100,000		1,190,500,000
Different income		-		-		-
Other liabilities		309,700,000		685,800,000		303,300,000
Total assets	23,086,300,000	23,086,300,000	18,150,900,000	18,150,900,000	13,432,500,000	13,432,500,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	5,400	4,800	3,900
Equity ratio	76.15%	76.65%	75.19%
Debt-equity ratio	31.32%	30.46%	33.00%

Others

	2023	2022	2021
Tax Expense Rate	17.36%	21.51%	14.22%

VERTEX PHARMACEUTICALS INC.

ISIN: US92532F1003 WKN: 92532F100 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	9,839,000,000	8,748,200,000	7,604,400,000
Net income	3,619,600,000	3,322,000,000	2,342,100,000
EBIT	3,586,742,720	3,900,672,160	2,624,239,200
Operating income before taxes	4,379,800,000	4,232,400,000	2,730,400,000
Cash Flow	3,537,300,000	4,129,900,000	2,643,500,000
Net interest income	570,600,000	89,800,000	-56,600,000
Research and development expenses	3,162,900,000	2,642,800,000	3,051,100,000
Income taxes	760,200,000	910,400,000	388,300,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,715,630	1,716,105	1,835,975

Board of Directors

Members of Management Board

Jeffrey Leiden	Chairman of Board of Directors
Alan Garber	Member of Board of Directors
Sangeeta Bhatia	Member of Board of Directors
Bruce Sachs	Member of Board of Directors
Diana McKenzie	Member of Board of Directors
Lloyd Carney	Member of Board of Directors
Michel Lagarde	Member of Board of Directors
Nancy Thornberry	Member of Board of Directors
Suketu Upadhyay	Member of Board of Directors
Terrence Kearney	Member of Board of Directors
Reshma Kewalramani	Chairman of Managing Board
David Altshuler	Member of Executive Committee
Amit K. Sachdev	Member of Executive Committee
Bastiano Sanna	Member of Executive Committee
Carmen Bozic	Member of Executive Committee
Charles F. Wagner	Member of Executive Committee
E. Morrey Atkinson	Member of Executive Committee
Jonathan Biller	Member of Executive Committee
Nia Tatsis	Member of Executive Committee
Stuart A. Arbuckle	Member of Executive Committee